Since its emergence, the COVID-19 pandemic had a dramatic impact on the public health
worldwide and it scarred the medical, economical, and social determinants of health. Even …

Low molecular weight heparin, enoxaparin, has been one of most used drugs to fight the
SARS-CoV-2 pandemic. Pharmacological properties of heparin recognize its specific ability …

Background: critically ill patients with SARS-CoV-2 infection present a hypercoagulable
condition. Anticoagulant therapy is currently recommended to reduce thrombotic risk …

Background The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and
a potential benefit of anticoagulation therapy has been documented for prevention of …

Background Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to
COVID-19 related poor outcomes, including thrombosis and death, due to the advanced …

Coagulation predominant-type coagulopathy such as microthrombosis and
macrothrombosis is a well-known recognised complication found in COVID-19 infected …

Purpose To report ischemic and haemorrhagic abdominal complications in a series of
COVID-19 patients. To correlate these complications with lung involvement, laboratory tests …

Background: This study was conducted to evaluate the technical and clinical success of
trans-arterial embolization (TAE) as a treatment of gastrointestinal bleeding (GIB) in …

Since the early days of the pandemic, there have been several reports of cerebrovascular
complications during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

COVID‐19 is a respiratory illness that affects the human body in many different ways. The
disease carries both thrombotic and hemorrhagic complications, especially in those patients …